Ulf Petrausch
Ulf Petrausch has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Alexander Rheinhard Siebenhuener
Department of Oncology, University Hospital Zurich, Zurich, Switzerland
1 shared publication- Andrea Gaisser
Deutsches Krebsforschungszentrum
1 shared publication - Andreas Müller
Cantonal Hospital Winterthur, Department of Medical Oncology, Brauerstrasse 15, 8401, Winterthur, Switzerland
1 shared publication - Armin Gerger
Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
1 shared publication - Axel Mischo
Department of Medical Oncology and Hematology, University Hospital Zurich (USZ), Rämistrasse 100, CH-8891, Zurich, Switzerland.
1 shared publication Axel Muendlein
Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria
1 shared publication
Latest Publications
- 23 April 2024
- Published by Springer Nature
- p. 807-819
Klinische Krebsforschung
- 23 April 2024
- Published by Springer Nature
- p. 139-191
Medikamentöse Tumortherapie
- 23 April 2024
- Published by Springer Nature
- p. 911-928
Seltenere solide Tumoren
- 1 September 2019
- Published by Hogrefe Publishing Group in Therapeutische Umschau
- Vol. 76 (4) , 195-198
Immuntherapie – Nebenwirkungen und -management
Zusammenfassung. Die Checkpointblockade ist eine wichtige therapeutische Säule in der Behandlung von Patienten mit Krebserkrankungen geworden. Im Rahmen dieser Entwicklung der letzten 10 Jahre wurde klar, dass diese neue Substanzklasse aufgrund seiner immunmodulatorischen Eigenschaften ein ganz besonderes Nebenwirkungsprofil aufweist, dass ein spezielles Management der unerwünschten Wirkungen zur Folge haben muss. Nur das Wissen um diese unerwünschten Wirkungen erlaubt den therapeutischen und damit auch erfolgreichen Einsatz dieser Substanzklasse. Da die unerwünschten Wirkungen sehr unterschiedlich und zeitlich sehr versetzt auftreten können, muss das Wissen um diese unerwünschten Nebenwirkungen breit in den Behandlungsteams verteilt sein, damit Symptome der unerwünschten Nebenwirkungen rasch erkannt werden können und die entsprechenden Massnahmen in koordinierte Weise ergriffen werden können. Dieser Artikel möchte einen Beitrag zum besseren Erkennen und Management der unerwünschten Nebenwirkungen von Checkpoint-Inhibitoren leisten.
- 1 September 2019
- Published by Hogrefe Publishing Group in Therapeutische Umschau
- Vol. 76 (4) , 195-198
Immuntherapie – Nebenwirkungen und -management
Zusammenfassung. Die Checkpointblockade ist eine wichtige therapeutische Säule in der Behandlung von Patienten mit Krebserkrankungen geworden. Im Rahmen dieser Entwicklung der letzten 10 Jahre wurde klar, dass diese neue Substanzklasse aufgrund seiner immunmodulatorischen Eigenschaften ein ganz besonderes Nebenwirkungsprofil aufweist, dass ein spezielles Management der unerwünschten Wirkungen zur Folge haben muss. Nur das Wissen um diese unerwünschten Wirkungen erlaubt den therapeutischen und damit auch erfolgreichen Einsatz dieser Substanzklasse. Da die unerwünschten Wirkungen sehr unterschiedlich und zeitlich sehr versetzt auftreten können, muss das Wissen um diese unerwünschten Nebenwirkungen breit in den Behandlungsteams verteilt sein, damit Symptome der unerwünschten Nebenwirkungen rasch erkannt werden können und die entsprechenden Massnahmen in koordinierte Weise ergriffen werden können. Dieser Artikel möchte einen Beitrag zum besseren Erkennen und Management der unerwünschten Nebenwirkungen von Checkpoint-Inhibitoren leisten.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15083
The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer.
E15083 Background: The tumor immune infiltrate and organized lymphocytic aggregates within the tumor microenvironment, known as tertiary lymphoid structures (TLS), play a critical role in cancer. We hypothesize that the maturation stage of TLS harbors prognostic information on recurrence risk in patients (pts) with non-metastatic colorectal cancer (nmCRC). Methods: In a comprehensive immunofluorescence and clinical analysis of 111 pts with UICC stage II & III nmCRC (median age: 65 yrs; female: n = 53 (48%); stage III: n = 69 (62%)), we quantified the number and maturation status of tumor-associated TLS in baseline surgical specimens:[1] Early TLS (E-TLS, composed of dense lymphocytic aggregates without follicular dendritic cells (FDCs), [2] Primary follicle-like TLS (PFL-TLS, having FDCs but no germinal center (GC) reaction), and [3] Secondary follicle-like TLS (SFL-TLS, having an active GC reaction). The 3-year incidence of recurrence was the primary endpoint of this study, which occurred in 19 pts (3-year recurrence risk = 18.3%). Results: Most TLS formed in tissue adjacent to the tumor. The median number of TLS/mm of tumor perimeter was 1.0 [25th-75th percentile: 0.5-1.7]. The average proportions of different TLS maturation stages were 56% of E-TLS [40-78], 20% of PFL-TLS [6-37], and 16% of SFL-TLS [0-32]. A structural equation model was fitted to summarize the TLS counts and maturation stages into a TLS maturation immunoscore for predicting recurrence. 3-year recurrence risks were 31.7% (95%CI: 17.2-47.3), 15.9% (5.7-30.5), and 9.4% (2.4-22.4) in pts in the 1st, 2nd, and 3rd tertile of the score (Gray’s test p = 0.05). A higher score was significantly associated with a lower recurrence risk (Hazard ratio (HR) for 10 units increase = 0.76, 95%CI: 0.59-0.97, p = 0.03), and this association prevailed in multivariable analysis adjusting for age, ECOG performance status, stage, and adjuvant chemotherapy (Adjusted HR = 0.73, 0.54-0.99, p = 0.05). Conclusions: Tumors of nmCRC pts with a very low risk of recurrence are characterized by an increased fraction of mature TLS comprising FDCs and GCs. If confirmed prospectively, adjuvant chemotherapy may be avoided in nmCRC pts with a high TLS maturation score.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15083
The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer.
E15083 Background: The tumor immune infiltrate and organized lymphocytic aggregates within the tumor microenvironment, known as tertiary lymphoid structures (TLS), play a critical role in cancer. We hypothesize that the maturation stage of TLS harbors prognostic information on recurrence risk in patients (pts) with non-metastatic colorectal cancer (nmCRC). Methods: In a comprehensive immunofluorescence and clinical analysis of 111 pts with UICC stage II & III nmCRC (median age: 65 yrs; female: n = 53 (48%); stage III: n = 69 (62%)), we quantified the number and maturation status of tumor-associated TLS in baseline surgical specimens:[1] Early TLS (E-TLS, composed of dense lymphocytic aggregates without follicular dendritic cells (FDCs), [2] Primary follicle-like TLS (PFL-TLS, having FDCs but no germinal center (GC) reaction), and [3] Secondary follicle-like TLS (SFL-TLS, having an active GC reaction). The 3-year incidence of recurrence was the primary endpoint of this study, which occurred in 19 pts (3-year recurrence risk = 18.3%). Results: Most TLS formed in tissue adjacent to the tumor. The median number of TLS/mm of tumor perimeter was 1.0 [25th-75th percentile: 0.5-1.7]. The average proportions of different TLS maturation stages were 56% of E-TLS [40-78], 20% of PFL-TLS [6-37], and 16% of SFL-TLS [0-32]. A structural equation model was fitted to summarize the TLS counts and maturation stages into a TLS maturation immunoscore for predicting recurrence. 3-year recurrence risks were 31.7% (95%CI: 17.2-47.3), 15.9% (5.7-30.5), and 9.4% (2.4-22.4) in pts in the 1st, 2nd, and 3rd tertile of the score (Gray’s test p = 0.05). A higher score was significantly associated with a lower recurrence risk (Hazard ratio (HR) for 10 units increase = 0.76, 95%CI: 0.59-0.97, p = 0.03), and this association prevailed in multivariable analysis adjusting for age, ECOG performance status, stage, and adjuvant chemotherapy (Adjusted HR = 0.73, 0.54-0.99, p = 0.05). Conclusions: Tumors of nmCRC pts with a very low risk of recurrence are characterized by an increased fraction of mature TLS comprising FDCs and GCs. If confirmed prospectively, adjuvant chemotherapy may be avoided in nmCRC pts with a high TLS maturation score.
- 1 October 2013
- Vol. 33 (10) , 4189-201
Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
Tumors can be targeted by the adoptive transfer of chimeric antigen receptor (CAR) redirected T-cells. Antigen-specific expansion protocols are needed to generate large quantities of redirected T-cells. We aimed to establish a protocol to expand functional active NY-ESO-1-specific redirected human CD8(+) T-cells. The anti-idiotypic Fab antibody A4 with specificity for HLA-A 0201/NY-ESO-1157-165 was tested by competition assays using a HLA-A 0201/NY-ESO-1157-165 tetramer. HLA-A 0201/NY-ESO-1157-165 redirected T-cells were generated, expanded and tested for CAR expression, cytokine release, in vitro cytolysis and protection against xenografted HLA-A 0201/NY-ESO-1157-165-positive multiple myeloma cells. A4 demonstrated antigen-specific binding to HLA-A 0201/NY-ESO-1157-165 redirected T-cells. Expansion with A4 resulted in 98% of HLA-A 0201/NY-ESO-1157-165 redirected T-cells. A4 induced strong proliferation, resulting in a 300-fold increase of redirected T-cells. After expansion protocols, redirected T-cells secreted Interleukin-2, (IL-2), interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα) and lysed target cells in vitro and were protective in vivo. A4 expanded HLA-A 0201/NY-ESO-1157-165 redirected T-cells with preservation of antigen-specific function.
- 1 October 2013
- Vol. 33 (10) , 4189-201
Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
Tumors can be targeted by the adoptive transfer of chimeric antigen receptor (CAR) redirected T-cells. Antigen-specific expansion protocols are needed to generate large quantities of redirected T-cells. We aimed to establish a protocol to expand functional active NY-ESO-1-specific redirected human CD8(+) T-cells. The anti-idiotypic Fab antibody A4 with specificity for HLA-A 0201/NY-ESO-1157-165 was tested by competition assays using a HLA-A 0201/NY-ESO-1157-165 tetramer. HLA-A 0201/NY-ESO-1157-165 redirected T-cells were generated, expanded and tested for CAR expression, cytokine release, in vitro cytolysis and protection against xenografted HLA-A 0201/NY-ESO-1157-165-positive multiple myeloma cells. A4 demonstrated antigen-specific binding to HLA-A 0201/NY-ESO-1157-165 redirected T-cells. Expansion with A4 resulted in 98% of HLA-A 0201/NY-ESO-1157-165 redirected T-cells. A4 induced strong proliferation, resulting in a 300-fold increase of redirected T-cells. After expansion protocols, redirected T-cells secreted Interleukin-2, (IL-2), interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα) and lysed target cells in vitro and were protective in vivo. A4 expanded HLA-A 0201/NY-ESO-1157-165 redirected T-cells with preservation of antigen-specific function.